Sinopharm Capital

4inLook is a retail company based in Shanghai, China, specializing in color contact lenses. Founded in 2008, it operates over 300 specialty stores primarily located in shopping centers within first- and second-tier cities. The company offers more than 200 designs of color contact lenses targeted at women aged 18 to 30. In addition to its physical retail presence, 4inLook has expanded its operations online through platforms like Tmall, allowing customers to experience a seamless shopping experience. Consumers can place orders online, pick them up in-store, and make appointments for product trials, thereby enhancing their purchasing convenience.

Metanovas Biotech specializes in the development of nutraceutical and cosmeceutical products utilizing advanced AI technology. The company offers a diverse product pipeline that includes pharmaceuticals, nutritional supplements, functional foods, and cosmetics, aimed at enhancing health and wellness for consumers. Metanovas employs an AI-enabled platform for drug and disease discovery, leveraging machine learning to identify novel disease targets, screen potential drugs, and optimize existing medications for new uses. This innovative approach allows for a more efficient generation of insights and the discovery of effective treatments, fundamentally transforming the intersection of science and artificial intelligence in health product development.

Artivila Therapeutics is a pharmaceutical company established in 2018 and based in Shenzhen, China. The company specializes in biotechnology and is dedicated to improving patient outcomes through innovative drug discovery. Utilizing an AI-powered platform, Artivila focuses on developing new therapeutic solutions for neurodegenerative diseases, cancers, and autoimmune diseases. Its integrated approach aims to consistently and efficiently deliver first-in-class drug candidates, positioning Artivila at the forefront of pharmaceutical research and development.

CytoNiche is engaged in the development of 3D micro-organization engineering technology, primarily for stem cell research. The company utilizes technology derived from Tsinghua University to create innovative solutions such as automated and intelligent stem cell culture amplification processes. Its offerings include high-quality stem cell cultures, injectable 3D micro-tissue treatments, and 3D drug screening microcarriers, which facilitate extensive drug screening operations. CytoNiche aims to provide reliable 3D micro-tissue products and services tailored for research institutes, clinical organizations, stem cell companies, and drug research enterprises, thereby advancing the capabilities in stem cell research and drug development.

Xishan is a medical device company based in Chongqing, China, specializing in the research, development, manufacturing, and sale of surgical instruments. Founded in 1992, it focuses on minimally invasive surgical tools and provides essential equipment for various surgical operations, including neurosurgery, orthopedics, ENT, and plastic surgery. The company's main offerings include surgical power devices, endoscope systems, and consumables designed for procedures such as bone cutting, grinding, and milling. With a commitment to advancing surgical technology, Xishan plays a significant role in enhancing surgical efficacy and patient outcomes in hospitals.

Sumgen is an antibody drug developer focused on creating innovative therapeutic antibody drugs for the treatment of tumors and other diseases. The company specializes in immunotherapy and immunodiagnosis, employing advanced technologies such as computer-aided design and mammalian cell display to screen and optimize antibody candidates. By leveraging its unique research and development methodologies, Sumgen aims to produce effective antibody drugs that provide patients with targeted treatment options for major diseases, including cancer.

Longhui Medical is a medical robotics R&D company focused on joint replacement surgery robots, product development, sales, and service.

Sepax Technologies is a biotechnology firm specializing in chromatography products aimed at the separation and purification of pharmaceuticals and biologics. The company provides a diverse range of offerings, including liquid chromatography columns, bulk resins, and systems that cater to various modalities such as size exclusion chromatography, ion exchange, hydrophobic interaction chromatography, affinity chromatography, and reversed-phase chromatography. These products are designed to assist biological researchers and scientists in achieving high-resolution, high-efficiency, and high-recovery separations of proteins, oligonucleotides, peptides, and other biomolecules. Additionally, Sepax Technologies offers method development services to further support its clients in their research endeavors.

Shanghai Ouyi Biomedical Technology Co., Ltd., established in 2009, is a high-tech enterprise of multi-omics testing services with "specialization, specialization and new". It has built a multi-omics testing platform covering nucleic acid, protein, and metabolism. Big data analysis platform combined with multi-omics. For pharmaceutical, food and daily chemical companies; life sciences, medicine and clinical research fields, provide drug target discovery, pharmacological efficacy and safety evaluation, disease molecular marker screening, pathogenic bacteria and drug resistance traceability, life development research and Multi-level and multi-omics testing services and solutions for disease occurrence and development research.

Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.

Geneus develops and commercializes gene sequencers and reagents. The core of its technology is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and it realizes single-molecule nucleic acid sequencing through an integrated chip system.

Yikon Genomics Co., Ltd. is a prominent provider of genetic analytical products and services, focusing on single cell sequencing for genetic research and in vitro diagnostics. The company specializes in patented MALBAC technology, offering a range of kits, including those for single cell whole genome amplification, which are applicable in various analyses such as copy number variation and single nucleotide variation. Yikon's solutions, particularly MALBAC-PGS and MALBAC-PGD, deliver comprehensive embryo testing results, assisting physicians in selecting embryos with balanced chromosomal copy numbers and minimizing the risk of inheriting known genetic diseases. Additionally, Yikon provides single cell DNA genome sequencing and whole genome re-sequencing services, aimed at enhancing cancer diagnostics and improving reproductive health outcomes. Founded in 2012 and based in Beijing, China, Yikon Genomics is committed to advancing precision medicine and supporting successful pregnancies through innovative genetic solutions.

FutureGen is a biopharmaceutical company focused on developing innovative biologics in the fields of immunology and cancer. The company utilizes its advanced Structure-based Targeted Evolution Platform (STEP) to efficiently screen and produce high-quality antibodies aimed at discovering new drug treatments. By integrating various technologies, FutureGen aims to enhance the development of antibody drugs that provide improved therapies for cancer and related diseases. The company possesses expertise in medication development, clinical research, and quality control, positioning it to make significant contributions to the biopharmaceutical industry and improve patient outcomes.

Beijing Biostar Technologies, Ltd. is a biotechnology company based in Beijing, China, founded in 2002. The company specializes in the development of anti-tumor chemotherapy biopharmaceuticals, focusing on the innovation and formulation of small molecule chemical drugs for cancer treatment. Led by a team of Chinese scientists, Biostar engages in biomedical development and technology transfer, offering technical service consulting as part of its operations. The company is recognized for its pioneering work in creating new anti-cancer drugs, including the development of epothilone, and its technologies are considered to be at an internationally advanced level.

Huiyi Huiying is an international cloud computing, large data & AI tech that has created a digital medical imaging and tumor radiotherapy platform. It has also built a video intelligent screening system, leak detection system and the image Depth applied to the tumor, cardiovascular, acute abdomen and other single disease of artificial intelligence assisted diagnosis and treatment system.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. It specializes in developing complement-targeted therapies aimed at treating immune-mediated diseases. The company focuses on pioneering drug discovery related to the complement system, with the goal of providing transformative therapies for individuals suffering from complement-mediated conditions.

Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.

MEDx is a company specializing in precision medicine solutions aimed at enhancing clinical development. Founded in 2013 and headquartered in Suzhou, Jiangsu, MEDx employs translational science to advance diagnostic technologies related to nucleic acids and proteins. Its comprehensive services include biomarker development, Companion Diagnostics, Point-of-Care development, clinical testing, and the commercialization of medical products. By focusing on individualized treatment, MEDx seeks to improve patient outcomes through its innovative approaches in the healthcare sector.

Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies.

SinoTau is a comprehensive solution provider focused on both generic and innovative pharmaceuticals. The company specializes in the early development of antibody biopharmaceuticals and conducts research on a range of medications aimed at treating cancers, neurological disorders, and autoimmune diseases. With expertise in medicinal chemical synthesis, generic drug analysis, and pharmaceutical preparations, SinoTau supports the biotechnology industry through targeted drug development. Their work is underpinned by advanced diagnostic technologies and monoclonal antibody innovations, positioning them as a key player in the fields of cardiovascular health, neurodegeneration, and oncology.

GenFleet Therapeutics, based in Shanghai, China, is a biotechnology company focused on the research and development of therapeutic molecules aimed at cancer treatment. Founded in 2017, the company specializes in creating innovative molecular pharmaceuticals and antibody drugs that target various cancer systems. GenFleet's work involves developing signal transduction regulators, tumor microenvironment modulators, and transcription factors, among other therapeutic agents. The company's mission is to provide effective medical solutions that can reactivate tumor-specific immune responses and enhance the body's own immune system in combating cancer. With a commitment to advancing cancer therapies, GenFleet serves both domestic and international markets.

ArteryFlow is a developer of advanced diagnostic systems that leverage artificial intelligence, computational fluid dynamics, and 3D medical image reconstruction. The company specializes in creating software for analyzing CT scans and ECG results, which enhances the ability of healthcare professionals to deliver faster and more precise diagnoses. By integrating big data technologies, ArteryFlow offers intelligent and image-assisted diagnostic solutions, along with technical training and guidance for users across various sectors, including scientific research institutions, hospitals, and clinics. The company's innovative approach includes automated grid generation and virtual therapy, aiming to improve diagnostic accuracy and efficiency in medical settings.

Baicare is a company focused on enhancing clinical microbiological testing and promoting the appropriate use of antibiotics. Utilizing advanced microfluidic chips and gene detection technology, Baicare offers intelligent automated nucleic acid detection products tailored for clinical hospitals. These products enable rapid and accurate identification of pathogenic bacteria and their drug resistance, assisting healthcare professionals in formulating effective treatment plans while minimizing patient suffering and reducing overall medical costs. The company has experienced significant growth and garnered financial support through initiatives such as the National Science and Technology Major Project. Baicare has applied for over 20 patents related to its technology and has been recognized as a National High-Tech Enterprise, gaining the attention of both medical experts and investors.

Synyi is a provider of an artificial intelligence-powered medical data platform designed to enhance medical research, healthcare, and patient services through big data applications. The company specializes in utilizing natural language processing technology to structure and standardize medical texts, employing techniques such as lexical, syntactic, and semantic analysis. This enables hospitals to implement smart medical systems that improve access to critical information. The core team at Synyi consists of experts from prestigious universities and leading companies, with significant achievements in artificial intelligence and medical informatics. Their work has been recognized in numerous national and municipal projects, along with the publication of over 20 papers in top international journals and presentations at major medical conferences.

Novena Global Lifecare is a unique integrated Healthcare platform.

Suzhou And Science Technology Development Corp, established in 2006 and located in Zhangjiagang, China, specializes in the manufacturing of surgical instruments and medical devices. The company focuses on developing products primarily for use in operating rooms, emergency rooms, and treatment rooms. Its product portfolio includes a range of innovative solutions such as the "AND" brand minimally invasive vertebroplasty system, medical vacuum drainage systems, high-pressure pulse irrigation systems, single-use irrigators, external fixation systems, and DC orthopedic drill chainsaws. Through its commitment to advancing medical technology, the company aims to enhance surgical procedures and patient care.

Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform. After users place orders on the mobile app, drugs will be delivered to their homes within half an hour.

Kanglu Bio is positioned to provide clinical diagnosis and guidance for clinical drug molecular diagnostic products and clinical molecular diagnostics overall service providers for clinical hospitals and third-party clinical independent testing institutions. The products and services are mainly used in cardiovascular and cerebrovascular diseases. Major diseases such as tumors and cancer.

Skynor Medical is a supplier of medical equipment. Their products include peripheral vascular stent systems, distal access catheters, microcatheters, thrombectomy devices, and balloon dilatation catheters.

Virogin Biotech Ltd., founded in 2015 and based in Vancouver, Canada, focuses on developing innovative oncolytic virus therapeutics aimed at treating cancer. Utilizing its proprietary Synerlytic™ technical platform, the company enhances cancer treatment by harnessing immunological principles to create therapies that stimulate and amplify the body's immune response against tumors. Virogin's approach is centered on leveraging multiple payload expressions to generate a robust and transient antiviral immune response, thereby improving systemic antitumor immunity. With its commitment to advancing immunotherapy, Virogin aims to establish itself as a leader in the field of immuno-oncology.

GenFleet Therapeutics, based in Shanghai, China, is a biotechnology company focused on the research and development of therapeutic molecules aimed at cancer treatment. Founded in 2017, the company specializes in creating innovative molecular pharmaceuticals and antibody drugs that target various cancer systems. GenFleet's work involves developing signal transduction regulators, tumor microenvironment modulators, and transcription factors, among other therapeutic agents. The company's mission is to provide effective medical solutions that can reactivate tumor-specific immune responses and enhance the body's own immune system in combating cancer. With a commitment to advancing cancer therapies, GenFleet serves both domestic and international markets.

Dr. Yu Pediatrics Clinics is a healthcare provider based in Chongqing, China, specializing in pediatric services. The clinic focuses on delivering comprehensive medical care to children, addressing a range of health issues from routine check-ups to specialized treatments. By prioritizing child-friendly practices and environments, Dr. Yu Pediatrics Clinics aims to ensure a positive healthcare experience for both children and their families. The clinic's commitment to quality care positions it as a trusted resource for pediatric health in the region.

LinaTech is a healthcare company specializing in the development and manufacturing of precision radiotherapy equipment for tumor treatment. The company creates informatics software designed to enhance the management of cancer clinics, radiotherapy centers, and medical oncology practices. Additionally, LinaTech produces image guidance series products and stereotactic radiotherapy equipment, equipping medical institutions with advanced tools for the calculation, positioning, treatment, and verification of radiotherapy procedures. Through its innovative solutions, LinaTech aims to improve the effectiveness and accuracy of cancer treatment.

Eccogene is a clinical stage biopharmaceutical company focused on developing therapeutic solutions for unmet medical needs, particularly in the areas of metabolism and immune-related diseases. The company specializes in disease biology, medicinal chemistry, and translational science, aiming to create immunological pharmaceuticals at the molecular level to address complex chronic conditions such as obesity and diabetes. Through its innovative approach, Eccogene is building a pipeline of metabolic drugs designed to enhance patient outcomes and improve health conditions related to these chronic diseases.

Topsuper specializes in R&D, production and sales of medical equipment.

Ansun Biopharma, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies to prevent and treat serious human diseases. The company specializes in host-directed anti-viral therapies, which aim to combat respiratory viral infections, including various strains of influenza and parainfluenza viruses. Its lead product candidates include Fludase, designed for the prophylaxis and treatment of respiratory infections, and Viradin, an intravenous therapeutic for sepsis and viral hemorrhagic fevers caused by pathogens such as Ebola and Marburg viruses. Additionally, Ansun Biopharma has developed TOSAP, a formulation technology for drug delivery using microspheres and nanospheres. Founded in 2003, the company was previously known as NexBio, Inc. before rebranding in 2011.

Eyebright Medical Technology (Beijing) Co Ltd is dedicated to the research, development, production, and sales of ophthalmic medical devices aimed at improving eye health and vision. The company offers a diverse range of products, including intraocular lenses, IOL delivery systems, surgical instruments, optometric lenses, and eye drops, all designed to address various ophthalmic conditions such as cataracts, glaucoma, and refractive errors. In addition to its product offerings, Eyebright provides related services to support the effective use of its medical devices, contributing to advancements in eye care and treatment.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Ancare Medical operates clinics that specialize in providing psychological health services. The organization focuses on addressing both the symptoms and root causes of psychological distress, aiming to enhance the overall well-being of its patients. Ancare Medical offers online psychological consultation services and intelligent rehabilitation assistance, along with the diagnosis and treatment of various psychological conditions. Through these services, the company seeks to support individuals in achieving a happier and healthier life.

Virtual Incision is focused on developing innovative surgical solutions, specifically through its miniaturized robotic support device designed for colon resection. The company's flagship product, the MIRA (Miniaturized In vivo Robotic Assistant) Platform, is a pioneering device that aims to streamline surgical procedures by allowing for quick setup in the operating room without the need for heavy equipment. This technology is intended to assist surgeons in improving clinical outcomes while also addressing healthcare costs. Virtual Incision's approach represents a significant advancement in robotic-assisted surgery, with plans for future applications beyond colon resection.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

Joymed Technology specializes in the research and development, registration, and manufacturing of medical devices, providing comprehensive solutions tailored for medical equipment businesses. The company focuses on delivering innovative and reliable technology while ensuring high-quality standards in its products. By offering services such as device design, risk management, marketing, and product verification and validation, Joymed Technology enables its clients to develop and launch safe and affordable medical products efficiently. The company aims to become a trusted partner for both domestic and international medical device firms, particularly assisting small and medium-sized enterprises in navigating the complexities of the medical product market. Through flexible collaboration and optimized design processes, Joymed Technology seeks to accelerate mutual growth with its customers.

InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company specializes in targeted therapies, particularly for lung cancer, breast cancer, and gout. Its product pipeline includes small molecule drug candidates, such as D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in developing novel immuno-oncology therapies that can be used in conjunction with existing treatments like PD-1 antibodies for various cancer types. The company was co-founded by Dr. Yaolin Wang and other scientists with extensive experience in drug discovery at leading pharmaceutical firms, focusing on significant health challenges such as tumors and metabolic disorders.

FHNED is a company that offers a range of seawater desalination products and services. Their products include sea dew sea hydrogen water, hai dew still sparkling water, marine ecological water, compound fruit and vegetable juice drink, and more. The company's contact modes are mail, phone, and physical address.

Anbiping is a number of reagents and supporting devices have indeed been independently created by Anbiping, which focuses on tumour screening and correct diagnosis. Pathology is the main application department. It has been established that product lines for liquid-based cytology, polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization can be used to screen for and diagnose tumors based on everything from cell morphology to protein expression.

ZC511.com information is gathered, categories and services are provided, and the information flow, commodity flow, financial flow, and distribution flow are created by the pharmaceutical industry chain. Chinese patent medicines, chemical drug preparations, chemical raw materials, antibiotic preparations, antibiotic raw materials, biochemical medications, biological products, chinese medicinal materials, chinese herbal components, and other items are all part of their business.